RxDoctor Payments Data

Marc Maalouf, MD

Interventional Cardiology · Wynnewood, PANPI 1538591912

Payments from drug & device makers

$9,953in general payments, 2019–2025

Across 132 payments — averaging $75.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Boston Scientific$394
  • Inari Medical, Inc.$393
  • AstraZeneca$240
  • Getinge USA Sales, LLC$211
  • Abiomed$204
  • plus $508 from 10 others

What the payments were for

  • Grants$6,50065%
  • Food & beverage$3,43935%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,953 in reported general payments places this provider in the 50th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$92,507
Medicare patients
750
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$213,405
XareltoRivaroxaban51$43,420
EntrestoSacubitril/Valsartan23$22,322
JardianceEmpagliflozin14$12,869
ClopidogrelClopidogrel Bisulfate238$2,882
Metoprolol Succinate265$2,408
Atorvastatin Calcium191$2,089
Potassium Chloride122$1,606
Dofetilide18$1,561
Losartan Potassium115$1,285
Ezetimibe28$1,125
Metoprolol Tartrate171$1,054
Isosorbide Mononitrate ErIsosorbide Mononitrate103$997
Amlodipine Besylate165$902
Furosemide174$831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$213,405249 claims
NovartisEntresto$70$22,32223 claims
Boehringer IngelheimJardiance$43$12,86914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →